Released May 8, 2023, before the open
10-Q filed May 8, 2023, 38 days after period end · 0001628280-23-016255
Q1 2023 · 10-Q
Revenue$5.31M$5.31M +35.4% vs Q1 2022+26.9% vs Q4 2022
Net Income-$30.49M-$30.49M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.73-$0.73 N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$33,317,000N/M
Operating Cash Flow-$31,180,000N/M
Free Cash Flowderived-$31,816,000N/M
Margins · derived
Operating margin-627.6%+81.7 pt vs Q1 2022
Net margin-574.3%+112.3 pt vs Q1 2022
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $5.31M | $3.92M | $286.00K | $0.00 |
| Net Income | -$30.49M | -$26.91M | -$22.99M | -$13.95M |
| EPS Diluted | -$0.73 | -$0.65 | -$0.62 | -$2.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR